Amgen still head of class in CGRP-migraine

As Amgen and Lilly continue to expand their presence in the migraine prevention market, the former's first-in-class CGRP inhibitor is maintaining its lead in the space.

Amgen Inc. (NASDAQ:AMGN) and Eli

Read the full 308 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE